Cytek Biosciences, Inc.
CTKB
$3.77
-$0.05-1.31%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 75.23% | 114.56% | -137.78% | 9.37% | 64.51% |
| Total Depreciation and Amortization | 13.03% | 9.77% | 1.43% | 36.59% | 30.10% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -190.12% | 26.10% | 44.52% | 39.51% | -5.26% |
| Change in Net Operating Assets | -43.27% | 161.85% | 259.15% | -49.99% | 19.01% |
| Cash from Operations | -79.01% | 411.89% | 317.68% | 38.45% | 53.59% |
| Capital Expenditure | 40.40% | 23.98% | 19.80% | -12.28% | 77.03% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -99.58% | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -302.13% | -133.33% | -26.91% | 95.80% | 169.17% |
| Cash from Investing | -318.24% | -136.66% | -27.53% | 96.59% | 156.92% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.71% | -1.45% | 1.42% | 4.79% | -180.00% |
| Issuance of Common Stock | -32.11% | -66.67% | -15.04% | 149.26% | 24.49% |
| Repurchase of Common Stock | 79.56% | -41.03% | -156.41% | -159.65% | -48,976.06% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 89.22% | -46.05% | -892.13% | -- | -976.73% |
| Foreign Exchange rate Adjustments | 284.45% | -163.98% | 324.85% | 255.50% | 17.86% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1,688.55% | -148.67% | 1,132.59% | 100.90% | 109.52% |